CING, CINGW · CIK 0001862150 · operating
Cingulate Inc. is a biopharmaceutical company focused on developing pharmaceutical treatments for attention deficit/hyperactivity disorder (ADHD) and anxiety disorders using proprietary delivery platform technology. The company's development pipeline centers on three product candidates: CTx-1301 (dexmethylphenidate), currently in Phase 3 clinical trials for ADHD treatment; CTx-2103 (buspiram) in formulation development for anxiety and mental health disorders; and CTx-1302 (dextroamphetamine), for which the company plans to initiate clinical trials targeting ADHD across pediatric and adult populations.
The company operates as a pre-revenue or clinical-stage entity, with no established commercial revenue streams. Its business model centers on advancing product candidates through clinical development toward potential regulatory approval and commercialization. Cingulate is incorporated in Delaware and maintains its principal operations in Kansas City, Kansas, with a minimal operational footprint of 13 full-time employees, reflecting the typical structure of early-stage biopharmaceutical firms during the development phase.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-10.20 | $-10.20 | +60.8% | |
| 2023 | $-26.00 | $-26.00 | -1566.7% | |
| 2022 | — | $-1.56 | — | |
| 2021 | — | — | — |